-
Article
Author Correction: Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring
-
Article
Open AccessBlockade of leukemia inhibitory factor as a therapeutic approach to KRAS driven pancreatic cancer
KRAS mutations are present in over 90% of pancreatic ductal adenocarcinomas (PDAC), and drive their poor outcomes and failure to respond to targeted therapies. Here we show that Leukemia Inhibitory Factor (LIF...
-
Article
Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring
Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis largely owing to inefficient diagnosis and tenacious drug resistance. Activation of pancreatic stellate cells (PSCs) and consequent development of...
-
Article
Open AccessCell of origin and mutation pattern define three clinically distinct classes of sebaceous carcinoma
Sebaceous carcinomas (SeC) are cutaneous malignancies that, in rare cases, metastasize and prove fatal. Here we report whole-exome sequencing on 32 SeC, revealing distinct mutational classes that explain both ...